Adaptogenic Mushrooms in Ayurveda: Reishi, Lion’s Mane, and Cordyceps

Mushrooms do not have a simple or interchangeable place in classical Ayurvedic pharmacology. Modern products made from Ganoderma, Hericium, or Cordyceps should therefore not be presented as classical Ayurvedic remedies unless a precise textual or pharmacopoeial source is supplied.

This does not dismiss the growing scientific interest in Reishi, Lion’s Mane, and Cordyceps. It means that evidence from modern extracts must be described as modern evidence. Classical references to chatra or chatraka concern mushrooms used as foods and do not establish the rasa, guna, virya, vipaka, dosha action, or therapeutic indications of every fungus now sold as a supplement.

The useful question is not whether these products can be forced into an Ayurvedic category, but what the classical record actually says, what human trials have tested, and where marketing has moved beyond the evidence.

The Classical Position: Food Classification, Not a Modern Extract Monograph

Charaka Samhita, Sutrasthana 27, discusses mushrooms within Shaka Varga, the group of vegetables and edible plant materials. The passage prohibits sarpa-chatraka and describes other edible mushrooms as sheeta or cold, madhura or sweet, and guru or heavy. It does not identify modern species such as Ganoderma lucidum, Hericium erinaceus, or Ophiocordyceps sinensis.

The same passage does not justify the frequently repeated claim that all fungi are uniformly snigdha, abhishyandi, Kapha-increasing, or equivalent to a particular Ayurvedic medicine. Those qualities may be proposed by individual practitioners after observing a specific preparation, but they should not be attributed to Charaka without an exact supporting verse.

Botanical identification is also important. Translating chatra directly as an Agaricus species is more specific than the Sanskrit passage permits. A classical category based on visible food forms cannot automatically be converted into a modern taxonomic identification, especially when the products under discussion belong to different fungal genera and are prepared as powders, hot-water extracts, alcohol extracts, or cultured mycelia.

The Ayurvedic Pharmacopoeia of India is a collection of official standards for the drugs included in its published monographs. A manufacturer should therefore cite the relevant monograph before describing a mushroom product as having an API-established identity or Ayurvedic pharmacological profile. In the absence of such documentation, assigning an official Ayurvedic rasa, guna, virya, vipaka, or dosage would be misleading.

Classical caution remains relevant because Ayurveda considers digestion, preparation, dose, constitution, season, and disease state when judging whether a substance is suitable. Nevertheless, a concentrated extract cannot be assumed to behave exactly like a culinary mushroom. Extraction changes the chemical composition, so both traditional dietary considerations and preparation-specific scientific evidence must be considered.

Reishi or Lingzhi: Evidence Is Strongest for Adjunctive Study, Not Cancer Treatment

Reishi products are commonly marketed under the name Ganoderma lucidum. The constituents most often investigated include fungal polysaccharides, particularly beta-glucans, and lanostane-type triterpenoids commonly called ganoderic acids. Their relative amounts vary with species, fungal material, cultivation, extraction method, and manufacturing quality.

The most important clinical synthesis is the updated 2016 Cochrane review of Ganoderma lucidum used alongside conventional cancer treatment. It included five randomized controlled trials with a total of 373 participants. The evidence was judged insufficient to support Ganoderma as a first-line cancer treatment, and the trials did not establish an improvement in long-term survival.

Some immune measurements, including percentages of CD3, CD4, and CD8 lymphocytes, improved in pooled analyses. Natural-killer-cell activity showed only a marginal result, and the reviewers emphasized that the trials were small and methodologically weak. These findings support further research into adjunctive use; they do not justify claims that Reishi treats or cures cancer.

Laboratory studies describe several possible immunological and inflammatory pathways, including interactions between fungal beta-glucans and pattern-recognition receptors such as Dectin-1. Triterpenoids have also shown effects on inflammatory signalling in experimental models. These mechanisms are biologically interesting but should not be represented as proven clinical outcomes in humans.

Calling Reishi an Ayurvedic Rasayana is likewise an interpretive comparison rather than a classical classification. Rasayana is a defined Ayurvedic therapeutic discipline involving appropriate substances, conduct, diet, patient selection, and preparation. Similarities between a modern immune marker and an Ayurvedic concept do not establish textual identity with Guduchi, Amalaki, or another recognized Rasayana drug.

Dose and Extraction: What Can Actually Be Said

There is no universally validated Reishi dose that applies across powders and extracts. Human studies have used substantially different preparations, and labels reporting milligrams cannot be compared without knowing the extraction ratio, fungal material, species authentication, and measured constituents. Fixed advice such as “three grams for everyone” or “500 milligrams of dual extract twice daily” therefore exceeds the evidence.

Hot-water extraction is commonly used to obtain water-soluble polysaccharide-rich fractions. Ethanol or combined solvent procedures can recover additional triterpenoid fractions, but the presence of both fractions does not by itself prove that a dual extract is clinically superior. Clinical relevance depends on the actual preparation studied rather than on extraction terminology alone.

No clinical trial establishes warm milk, ghee, or another Ayurvedic anupana as necessary for Reishi absorption. Such advice should not be presented as classical or evidence-based. People who experience nausea, abdominal discomfort, diarrhoea, dry mouth, or another reaction should stop the product and discuss it with a qualified healthcare provider.

Lion’s Mane: Small Human Trials, Larger Preclinical Claims

Hericium erinaceus, commonly called Lion’s Mane, contains several groups of compounds investigated in laboratory models. Hericenones have mainly been reported from fruiting bodies, while erinacines are principally associated with cultured mycelium. Experimental research suggests that some preparations can influence nerve-growth-factor-related pathways, but direct proof of clinically meaningful NGF stimulation in the human brain remains limited.

The best-known clinical trial was published by Mori and colleagues in 2009. Thirty Japanese adults with mild cognitive impairment were randomized to Lion’s Mane or placebo. Participants took four 250-milligram tablets three times daily for 16 weeks. Because the active tablets contained 96% dry fruiting-body powder, the daily amount was approximately 2.88 grams of mushroom material, not 750 milligrams as is sometimes reported.

The treatment group improved on the Revised Hasegawa Dementia Scale at weeks 8, 12, and 16 compared with placebo. Scores declined during the four weeks after supplementation ended. The trial is encouraging but small, and it does not demonstrate prevention of dementia, permanent disease modification, or cognitive enhancement in healthy young adults.

A later randomized trial reported by Saitsu and colleagues evaluated adults aged 50 years and older who received 3.2 grams of fruiting-body powder daily for 12 weeks. Thirty-one participants were included in the analysis. Improvement was reported on the Mini-Mental State Examination, while the results were not uniformly positive across every cognitive test. The study therefore adds a preliminary signal rather than definitive proof.

Much of the enthusiasm for Lion’s Mane still comes from cell and animal experiments involving neurite growth, nerve growth factor, neuroinflammation, or erinacine-rich mycelial preparations. These studies may guide future trials, but they cannot establish that every commercial capsule reaches the brain, contains the studied compound, or produces the same effect in humans.

Describing Lion’s Mane as equivalent to Brahmi or Shankhapushpi is also inappropriate. Brahmi is included within the classical concept of Medhya Rasayana, whereas Lion’s Mane has no demonstrated classical Ayurvedic identity. A practitioner may compare their intended clinical roles, but that is a modern therapeutic analogy, not a textual synonym or a verified replacement.

Mycelium Versus Fruiting Body: Identity Matters More Than Slogans

Fruiting bodies and cultured mycelia are chemically different materials. A fruiting-body product may provide hericenones and fungal beta-glucans, while a specifically cultured mycelial preparation may provide erinacines. It is therefore inaccurate to claim that all mycelium is ineffective or that fruiting body is automatically superior for every purpose.

The quality problem arises when mycelium is grown on grain and the final material contains an undeclared or poorly quantified amount of residual substrate. Total polysaccharide testing cannot reliably distinguish fungal beta-glucans from starch or other alpha-glucans contributed by grain. A label may consequently display a large “polysaccharide” number without revealing how much is mushroom-derived beta-glucan.

The frequently recommended minimum of 20% beta-glucan is a commercial benchmark rather than a clinically validated therapeutic threshold for Lion’s Mane. A more defensible approach is to request measured beta-glucan and alpha-glucan values, species authentication, identification of fruiting body or mycelium, extraction information, and a batch-specific certificate of analysis.

Cordyceps: Correcting the Species and Exercise Claims

The famous caterpillar fungus is now generally called Ophiocordyceps sinensis; Cordyceps sinensis is an older name still found in publications and commercial labels. It has a documented history in Tibetan and Chinese medical traditions, but that history is not an Ayurvedic classical reference and should not be rewritten as one.

Wild O. sinensis is scarce and expensive. Commercial supplements may instead contain cultivated Cordyceps militaris, cultured mycelial products, or strains sold under designations such as CS-4. These materials are not chemically interchangeable, so the species, fungal part, strain, and cultivation method should be stated clearly.

The exercise study commonly cited for Cordyceps was published online in 2016 and in the 2017 volume of the Journal of Dietary Supplements. Hirsch and colleagues randomized 28 healthy adults to four grams daily of a mushroom blend containing Cordyceps militaris or to placebo. It was not a trial of one gram twice daily of a purified Cordyceps extract.

After one week, the study did not find significant treatment-by-time differences in the principal exercise variables. Only ten participants continued for an additional two weeks. In that small subgroup, mean VO2max increased by 4.8 millilitres per kilogram per minute in the mushroom group and by 0.9 in the placebo group, with a reported statistically significant interaction. Time to exhaustion and ventilatory threshold also increased in the extended-supplementation group.

These results are preliminary because the three-week comparison involved very few participants and used a multi-ingredient mushroom blend. The study does not establish a reproducible 7% increase in VO2max from pure C. militaris, nor does it prove enhanced mitochondrial ATP production in humans. Proposed roles for cordycepin, adenosine-related compounds, or hypoxia signalling remain primarily mechanistic or preclinical explanations.

Traditional Chinese descriptions involving Lung and Kidney systems should remain identified as Chinese medical concepts. Equating Cordyceps with Ashwagandha for ojas or with Pippali for respiratory action is a modern cross-system analogy, not an Ayurvedic textual attribution.

Combining Mushrooms with Classical Ayurvedic Herbs

The human trials discussed above tested particular mushroom preparations rather than formulas combining Reishi with Ashwagandha, Lion’s Mane with Brahmi, or Cordyceps with Pippali. They therefore cannot establish that these combinations are synergistic, safer, more bioavailable, or more effective than either component alone.

Mechanistic differences do not automatically prove clinical complementarity. Combining products may increase gastrointestinal effects, allergic reactions, medication interactions, expense, and uncertainty about which ingredient caused a benefit or adverse event. Beginning several concentrated products simultaneously also makes meaningful assessment difficult.

An Ayurvedic assessment may still consider agni, bowel function, appetite, diet, constitution, season, strength, current disease, and concurrent medicines before adding a new preparation. However, terms such as ama, ojas, or Rasayana should guide individualized Ayurvedic reasoning rather than serve as unverified explanations for modern pharmacological effects.

Safety and Populations Requiring Extra Caution

Short clinical studies generally report mild adverse effects, but the long-term safety of concentrated mushroom extracts is less certain. Product contamination, species substitution, variable extraction, allergies, and interactions can alter the risk beyond that observed in a controlled trial.

• Anticoagulant or antiplatelet treatment: Reishi may increase bleeding risk when combined with medicines that reduce clotting or platelet activity. Prescriber approval is advisable before use.
• Immunosuppressive treatment: Because Reishi preparations can influence immune responses, people taking immunosuppressants should not self-prescribe them as “immune boosters.”
• Cancer treatment: Mushroom products should not replace surgery, radiotherapy, chemotherapy, immunotherapy, or another prescribed treatment. Oncology teams should review any intended supplement.
• Pregnancy and breastfeeding: Adequate safety evidence for concentrated Reishi, Lion’s Mane, and Cordyceps supplements is lacking. Avoid routine use unless a qualified clinician specifically recommends it.
• Surgery: Disclose mushroom supplements to the surgeon and anaesthetist and follow their instructions about when to stop. A universal two-week rule has not been established for every product.
• Allergy: Anyone with a mushroom allergy or a previous hypersensitivity reaction should avoid unsupervised use. Lion’s Mane has rarely been associated with acute hypersensitivity.
• Liver symptoms: Reishi has been linked to rare reports of clinically apparent liver injury, although causality is often uncertain. Stop use and seek medical care for jaundice, dark urine, severe itching, or persistent upper-abdominal pain.
• Digestive intolerance: Nausea, abdominal discomfort, loose stools, bloating, or loss of appetite warrants dose review or discontinuation rather than automatic interpretation as “detoxification.”

Lion’s Mane has not been convincingly linked to clinically apparent liver injury in published LiverTox assessments, and Cordyceps has likewise not been associated with a clear pattern of acute liver injury. That is reassuring but does not guarantee that every commercial mixture, adulterated product, or high-dose extract is safe.

How to Evaluate a Mushroom Supplement

A trustworthy label should identify what the product actually contains. Large front-label claims such as “10:1,” “30% polysaccharides,” “full spectrum,” or “Ayurvedic adaptogen” do not substitute for authentication, compositional testing, and batch-level contaminant results.

The evidence is graduated rather than uniform. Reishi has been studied as an adjunct in small oncology trials, but it is not an established cancer treatment. Lion’s Mane has produced preliminary cognitive findings in small trials involving middle-aged or older adults, while many neurotrophic claims remain preclinical. Cordyceps-related exercise evidence is limited and preparation-specific.

These fungi may be biologically active and worthy of further research, but “natural,” “adaptogenic,” “immune boosting,” and “Ayurvedic” are not substitutes for accurate identity, realistic claims, careful patient selection, and competent clinical supervision. The classical record should be respected without inventing equivalences it does not contain.

Disclaimer: This article is for educational and informational purposes only and does not constitute medical advice. Mushroom extracts may interact with medicines and may not be appropriate during pregnancy, breastfeeding, cancer treatment, immune-mediated illness, bleeding disorders, liver disease, or before surgery. Consult a qualified Ayurvedic practitioner and a licensed healthcare provider familiar with your diagnoses and medications before starting, stopping, or combining any supplement. Do not use mushroom products as substitutes for prescribed treatment.

References

1. Charaka Samhita — Annapanavidhi Adhyaya
2. Ayurvedic Pharmacopoeia of India
3. Ayurvedic Pharmacopoeia of India
4. Natural Bio-Compounds from Ganoderma lucidum and Their Beneficial Biological Actions for Anticancer Application: A Review (2023), PubMed Central
5. Journals (journals.plos.org)
6. Ganoderma lucidum (Reishi mushroom) for cancer treatment (2016), PubMed Central
7. Edible Mushrooms and Beta-Glucans: Impact on Human Health (2021), PubMed Central
8. Neurohealth Properties of Hericium erinaceus Mycelia Enriched with Erinacines (2018), PubMed Central
9. Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial (2009), PubMed
10. Improvement of cognitive functions by oral intake of Hericium erinaceus (2019), PubMed
11. The Acute and Chronic Effects of Lion’s Mane Mushroom Supplementation on Cognitive Function, Stress and Mood in Young Adults: A Double-Blind, Parallel Groups, Pilot Study (2023), PubMed Central
12. Researchgate (researchgate.net)
13. A Systematic Review of the Mysterious Caterpillar Fungus Ophiocordyceps sinensis in Dong-ChongXiaCao ( Dōng Chóng Xià Cǎo) and Related Bioactive Ingredients (2013), PubMed Central
14. NCBI
15. Cordyceps militaris Improves Tolerance to High-Intensity Exercise After Acute and Chronic Supplementation (2017), PubMed
16. Cordyceps militaris Improves Tolerance to High-Intensity Exercise After Acute and Chronic Supplementation (2017), PubMed Central
17. Mskcc (mskcc.org)
18. NCBI
19. NCBI
20. NCBI
21. Webmd (webmd.com)
22. Analysis of heavy metal characteristics and health risks of edible mushrooms in the mid-western region of China (2024), PubMed Central